Paris, France – 6 July, 2010 – DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.The objectives of the clinical study are to demonstrate DBV Technologies’ EPicutaneous ImmunoTherapy (EPIT) using VIASKIN® PEANUT is safe and well tolerated in both adult and pediatric peanut allergy patients, and to determine an appropriate dosing regimen for further efficacy trials... DBV Technologies' Press Release -
About DBV Technologies,
DBV Technologies is a private French company focused on the development of innovative products for the diagnosis and treatment of food allergies.
DBV Technologies was founded in 2002 by leading French pediatricians, Professor Christophe Dupont (Head of the Neonatology Department in Paris at Saint Vincent Hospital), Doctor Pierre-Henri Benhamou and engineer Bertrand Dupont (Arts et Métiers Institute), with funding from ANVAR. Leading investors in DBV Technologies include Sofinnova, Apax Partners, Cap Decisif, Creagro and ALK-ABELLO.
DBV Technologies’ novel approach to food allergy diagnosis and treatment is focused on eliciting an immune response by targeting antigen presenting the skin epidermis. The antigens (allergens) are delivered to the skin using DBV Technologies’ unique worldwide patented delivery system, VIASKIN®... About DBV Technologies -
